This article is written by Hilary Tetenbaum and published in USA Today.
---
The battle against cancer has always been a challenge. Despite the revolutionary advancements in medical science, the battle still continues to be challenging. When it comes to canine cancer, the process right from diagnosis to treatment and cure becomes even tougher due to the complexities involved. However, ImpriMed, a California-based AI-driven precision medicine company has embarked on a mission to revolutionize the realm of canine cancer treatment. Its proprietary technology identifies the best-suited drug(s) for individual canine cancer patients.
In order to make its drug response predictions as accurate as possible, ImpriMed uses proprietary AI algorithms that rely on real-world clinical outcomes and patients’ live cell-based drug sensitivity data. This approach significantly helps oncologists by providing them with reliable predictions to choose the most suitable drugs for their patients. This method substantially eliminates the guesswork when it comes to drug selection and avoids unnecessary costs or side effects that might come with multiple drug trials. There are three major components in the service: Drug response and prognosis prediction, immune subtyping, and clonality analysis.
What sets ImpriMed apart from other players in the industry is its unique methodology and approach to canine cancer treatment. There are other companies doing precision medicine in veterinary oncology, and there are also companies utilizing AI in veterinary oncology. However, no other company in the veterinary oncology realm employs an AI-powered drug efficacy prediction the way ImpriMed uses it.
“Drug response and prognosis prediction is our core competence. And we are proud that ImpriMed is the only provider of such a promising solution powered by artificial intelligence in this sector. We believe that by employing machine learning, the complex, cumbersome process of quantifying the probabilities of each patient’s responses and survival specific to each drug can be done more precisely and accurately. We are committed to enhancing care and clinical outcome of canine lymphoma by assisting the processes of individualized treatment selection”, says Dr. Sungwon Lim, CEO and Co-founder of ImpriMed.
The proprietary technology developed by ImpriMed provides a precise drug response and prognosis prediction report. This report offers tailored insights for each individual patient. After analyzing a significant amount of data including both patients’ information such as age and their live cancer cell analytics, ImpriMed’s AI-powered model predicts efficacy of thirteen drugs that are commonly used to treat canine lymphoma.
In order to ensure the accuracy of its predictions, ImpriMed analyzes real-world, clinical outcomes of thousands of patients. In addition, ImpriMed also ensures an unprecedented turnaround time of a week or less when it comes to providing analysis results and predictive information for the given patient. It helps both the pet owners and the oncologists save valuable time and initiate the treatment as early as possible.
The service provided by ImpriMed has earned a significant reputation among oncologists and pet owners. Acknowledging the expertise of the company and the impact of its methodology on patients, several scientific journals featured ImpriMed’s technology. “We are extremely happy about the response we receive from the stakeholders. Within a short time since our inception, we have successfully contributed to improved outcomes of canine cancer patients. With our data-driven drug response prediction, we are committed to providing an improved cancer treatment methodology in the field of veterinary medicine” says Dr. Jamin Koo, Director and Co-founder.
Another notable aspect of the services provided by ImpriMed is its paperless approach and commitment to digitization. Pet owners and oncologists are provided with convenience throughout the process. The user-friendly website enables the users to access each step of the process from submitting the sample to receiving the result. Utilizing its proprietary transport media, ImpriMed also ensures that the viability of the live cancer cells is preserved during sample transportation. It ensures cells remain intact and results obtained are accurate.
The overwhelmingly positive feedback from pet owners is a testament to ImpriMed’s commitment and the impact of its methodology. Commenting on the experience with ImpriMed, the owner of patient Yoki said, “The ImpriMed test helped us make treatment decisions with Dr. Choy. It was tremendously helpful for us. We would recommend ImpriMed to other pet parents. Veterinary oncologists are experts in this field and we heavily relied on Dr. Choy to make treatment decisions for Yoki. We are confident in the treatment Yoki is getting and are happy for the time we are getting to spend with him”
Driven by an unwavering commitment and with an exceptional methodology, ImpriMed continues to transform the lives of many pets and their owners. ImpriMed’s drug response prediction technology revolutionizes the way we used to approach canine cancer and its treatment. Looking forward, the company seeks to expand its veterinary services to cats as well as dogs. Even further into ImpriMed’s future, its aims are to address human cancer types utilizing their expertise in live-cell analysis and AI.
